Replies to post #169179 on Biotech Values

[DewDiligence]

The chances of a patient that has failed both Sprycel and Tasigna responding to Bosulif are negligible in my opinion.

Bosulif gets some use the second-line setting, and such use will presumably increase if your conjecture about changes to the Tasigna label is borne out.